The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. - Wikidata - wikimedia - TriplyDB

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

http://www.wikidata.org/entity/Q35045001

about

Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders Endocannabinoid-mediated synaptic plasticity and addiction-related behavior Interaction between the cholecystokinin and endogenous cannabinoid systems in cued fear expression and extinction retention Memory encoding in hippocampal ensembles is negatively influenced by cannabinoid CB1 receptors Endocannabinoid signaling in the etiology and treatment of major depressive illness.Neural encoding of psychomotor activation in the nucleus accumbens core, but not the shell, requires cannabinoid receptor signaling.Cannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choice Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors Modulation of the serotonin system by endocannabinoid signaling A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research.Dysfunction in fatty acid amide hydrolase is associated with depressive-like behavior in Wistar Kyoto rats.Advances in pharmacotherapy for tobacco dependence.A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies.The endocannabinoid/endovanilloid system and depression.The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.Involvement of opioid system in antidepressant-like effect of the cannabinoid CB1 receptor inverse agonist AM-251 after physical stress in mice.Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.Involvement of the cannabinoid CB1 receptor in modulation of dopamine output in the prefrontal cortex associated with food restriction in rats.Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.Diacylglycerol Lipase α Knockout Mice Demonstrate Metabolic and Behavioral Phenotypes Similar to Those of Cannabinoid Receptor 1 Knockout Mice.Ultrastructural evidence for synaptic contacts between cortical noradrenergic afferents and endocannabinoid-synthesizing post-synaptic neurons.Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report.A possible role for the endocannabinoid system in the neurobiology of depression Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders.Role of the serotonergic system in alcohol dependence: from animal models to clinics.Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action.Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area.Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice.Changes in c-Fos Expression in the Forced Swimming Test: Common and Distinct Modulation in Rat Brain by Desipramine and Citalopram.The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction.Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex Role of endocannabinoid signaling in anxiety and depression.Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses Endocannabinoid-mediated control of synaptic transmission.

P2860

Q24534868-0DAF678F-417E-4348-A325-5987829FC80D Q24595389-A27FA2AF-9699-4A35-8380-86335CB073F5 Q24626361-C976C981-470E-4F60-89C1-CB711838C779 Q24645054-865AF55B-3F16-4C2E-BDDF-7AE76772CA5B Q27001139-43065C5A-1C86-404F-A07C-2774F0CF2151 Q29042501-6DAD08FE-AC84-4C21-A87D-C741766785CF Q30392035-0B320558-5AEF-4F89-BB35-7F479E0F0042 Q30465050-45E79D84-4AD4-4422-B4CB-5BF2330C186E Q30687668-6D289C82-5455-48EF-B9F7-7C162C36FECB Q33865196-3034AE48-B1B3-43B8-A953-86F391A4F6F7 Q34053352-54021BB6-1B69-4580-A16D-3853EECA7B7B Q34116825-0D99E921-07BD-466F-A4E9-3E51E5D038BF Q34167072-FD212325-DD57-449F-91A7-9836587684B4 Q34264449-AC1EEC5C-3D9C-44E2-8FC3-A390C7C11C2A Q34273681-2DC52D53-A4DD-49CE-9386-3F9E01A05DC0 Q34322083-ADC58B37-E667-4488-A002-3B37A13C4C24 Q34502250-E6CBEC09-055F-42E3-9CAC-7AAC8D9482B3 Q34567576-8534CE50-39D0-4DFB-8527-31965D18EC8B Q34626755-E3D1FF67-DF6B-4400-8686-805641A83FAB Q34674584-9C9B44C1-0FD2-44E6-8F2B-BD37E3DDF426 Q34798544-8A4CD860-BA8C-42B3-B9AE-7C8BB912E52A Q35121789-12003CC2-F47B-4B51-B2A3-F581C06F116A Q35532072-C4BE0970-6B1B-48B9-BC79-FEDD1C00FF2D Q35672654-A7B8C984-C4A2-44CD-AB16-51A0FDD280B3 Q35972392-68283984-8FED-4612-A7FA-FB9EE6B02F1E Q36174333-6E65C4E3-7222-4378-B25A-5BD32415FC38 Q36316074-780D2FB9-9330-46F6-9347-4C2FF831250D Q36358712-1CBDB3E7-4A10-4FA7-BA06-7FE770B86154 Q36425951-A88EFA50-7853-4D48-A276-C5481F174C83 Q36429331-6B6C0581-2EBE-4743-8FEA-D50F77E3CC3A Q36496715-E3326076-C634-413C-88BE-993F0E749903 Q36712228-DDAE0A5C-536E-44BE-9EA3-022C5588C665 Q36873051-404ED774-BB0D-4685-8C56-6A4639DBC678 Q37001332-6BA3E9AD-B755-4B40-8A84-9C82A3352FCE Q37090099-2820C2B8-4EED-4D68-92D5-A36D17671D81 Q37142233-015651F1-F734-4A1B-8904-519ECBC391A6 Q37240007-5F550990-4A6D-4A09-B319-6CAB16BA7885 Q37254797-8FEEE5A9-EC31-49E0-945D-BD80B0578AE1 Q37279826-DCDA743B-67CC-4CE7-86A0-036AB4158DAC Q37363621-04EE29FA-4AC9-41BC-8DB6-079FC2789165

P2860

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

http://www.wikidata.org/entity/Q35045001

description

2003 nî lūn-bûn

@nan

2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

The CB1 receptor antagonist SR ...... tions for therapeutic actions.

@en

type

label

The CB1 receptor antagonist SR ...... tions for therapeutic actions.

@en

prefLabel

The CB1 receptor antagonist SR ...... tions for therapeutic actions.

@en

P1433

Q35045001-148B60C1-0F73-4B5F-8709-24FE3BA98333

P1476

Q35045001-642D7A6D-1A7B-4B4D-86C6-04F388305933

P2093

Q35045001-053C39FD-F679-4B75-BA1C-759F0EED2F86

Q35045001-1FBF25DC-57B4-44F2-8CDB-F7F34ECEF066

Q35045001-53ACA1AA-0C0C-40FF-ACC1-E15E851F0C03

Q35045001-7B00290E-EA81-4B8F-9897-914149C4D408

Q35045001-BFA2D0F5-2CD6-42F6-9CA4-43D9EA376707

Q35045001-E5FB02D6-384B-48B2-A91F-BAE73E11631A

Q35045001-EE713D1E-FAB8-433E-9B55-CCA1FA5D5DB7

Q35045001-F1DB92EC-467F-4012-9DA9-798444A96912

P2860

Q35045001-04B8239E-EAEC-40AC-82C9-591906208234

Q35045001-077B17EF-2558-45AB-AFA5-9B42AA61DA9D

Q35045001-0B5DA210-29F5-4F80-BCE0-22A7E2263FCD

Q35045001-1E7AC773-F3A5-4BB7-B28A-D1218EF87C47

Q35045001-1EABAE3D-C4FC-47AA-A550-C1E0737F4F89

Q35045001-201B2A72-3610-400F-9B0D-E369E0F30596

Q35045001-2C7F3A0E-63B6-4BBC-A249-700FA0B599DC

Q35045001-34C46774-C9EA-4164-937A-8F2F9C5FEBC5

Q35045001-42056B96-BE40-448A-9AB0-D07E113B44B2

Q35045001-46F85B83-49C9-48CD-B6C7-5AC4EDC67FE5

P304

Q35045001-643F1866-6CFB-4494-9903-AC2FB093ECBF

P31

Q35045001-03346C58-C786-4378-8077-FBDD1CFF9264

P356

Q35045001-46E17DFA-E0C9-4E8C-AF08-6432FBF1CD48

P407

Q35045001-41028242-187B-4334-9B9F-4E49C4A6D1D3

P433

Q35045001-56A107C3-42CB-4E4D-BD31-A05FD650F62C

P478

Q35045001-D95FEA22-19FC-41EC-A482-3BA1DCEF10CD

P577

Q35045001-2CB97D32-73EF-4F09-A8E7-628022423288

P5875

Q35045001-321CD351-F68D-4A63-81A2-FD1D0EF55E7C

P698

Q35045001-5EC9D584-5819-47B1-9EC8-8CB31FB76DF9

P932

Q35045001-D85556B2-72CA-433A-9D6C-E4FC37CA80B4

P356

P1433

British Journal of Pharmacology

P1476

The CB1 receptor antagonist SR ...... tions for therapeutic actions.

@en

P2093

Craig Salhoff

http://www.w3.org/2001/XMLSchema#string

Eleni T Tzavara

http://www.w3.org/2001/XMLSchema#string

Frank P Bymaster

http://www.w3.org/2001/XMLSchema#string

George G Nomikos

http://www.w3.org/2001/XMLSchema#string

Jeffrey M Witkin

http://www.w3.org/2001/XMLSchema#string

Kenneth W Perry

http://www.w3.org/2001/XMLSchema#string

Richard J Davis

http://www.w3.org/2001/XMLSchema#string

Xia Li

http://www.w3.org/2001/XMLSchema#string

P2860

Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

Leptin-regulated endocannabinoids are involved in maintaining food intake

Behavioral despair in mice: a primary screening test for antidepressants

Fluoxetine increases norepinephrine release in rat hypothalamus as measured by tissue levels of MHPG-SO4 and microdialysis in conscious rats

Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis

Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction

CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum.

Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum.

Drug addiction as dopamine-dependent associative learning disorder.

P304

544-553

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJP.0705100

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

138

http://www.w3.org/2001/XMLSchema#string

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10890766

http://www.w3.org/2001/XMLSchema#string

P698

12598408

http://www.w3.org/2001/XMLSchema#string

P932

1573706

http://www.w3.org/2001/XMLSchema#string